Concepts (219)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Space Flight | 12 | 2019 | 166 | 0.910 |
Why?
|
| Weightlessness | 8 | 2019 | 81 | 0.760 |
Why?
|
| Astronauts | 7 | 2019 | 77 | 0.730 |
Why?
|
| Aerospace Medicine | 6 | 2008 | 39 | 0.600 |
Why?
|
| Radiation-Protective Agents | 3 | 2011 | 17 | 0.420 |
Why?
|
| Extraterrestrial Environment | 3 | 2007 | 8 | 0.340 |
Why?
|
| Medullary Sponge Kidney | 1 | 2008 | 2 | 0.290 |
Why?
|
| Radiation, Ionizing | 2 | 2007 | 38 | 0.280 |
Why?
|
| Linear Energy Transfer | 2 | 2007 | 9 | 0.280 |
Why?
|
| Immunotherapy, Active | 1 | 2007 | 18 | 0.270 |
Why?
|
| Radiation Injuries, Experimental | 1 | 2007 | 22 | 0.260 |
Why?
|
| Gamma Rays | 1 | 2007 | 41 | 0.260 |
Why?
|
| Urinary Catheterization | 1 | 2007 | 80 | 0.250 |
Why?
|
| Urogenital System | 1 | 2005 | 35 | 0.240 |
Why?
|
| Military Personnel | 1 | 2008 | 208 | 0.240 |
Why?
|
| Adjuvants, Immunologic | 1 | 2007 | 380 | 0.230 |
Why?
|
| Ultrasonography, Interventional | 1 | 2007 | 199 | 0.230 |
Why?
|
| Urinary Calculi | 2 | 2008 | 18 | 0.230 |
Why?
|
| Reproduction | 1 | 2005 | 214 | 0.210 |
Why?
|
| Gravitation | 2 | 2000 | 11 | 0.190 |
Why?
|
| Epithelial Cells | 1 | 2007 | 870 | 0.190 |
Why?
|
| Neck Pain | 1 | 2000 | 16 | 0.160 |
Why?
|
| Aircraft | 1 | 2000 | 22 | 0.160 |
Why?
|
| Cervical Vertebrae | 1 | 2000 | 107 | 0.150 |
Why?
|
| Ecological Systems, Closed | 2 | 2008 | 2 | 0.140 |
Why?
|
| Exercise Therapy | 1 | 2019 | 172 | 0.130 |
Why?
|
| Space Simulation | 2 | 2007 | 4 | 0.130 |
Why?
|
| Endoscopy | 1 | 1999 | 280 | 0.130 |
Why?
|
| Bone Density | 1 | 2019 | 351 | 0.130 |
Why?
|
| Dogs | 2 | 2007 | 604 | 0.120 |
Why?
|
| Telemedicine | 1 | 1999 | 488 | 0.100 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 3 | 2006 | 1302 | 0.100 |
Why?
|
| Penile Neoplasms | 1 | 1992 | 37 | 0.090 |
Why?
|
| Whole-Body Irradiation | 1 | 2011 | 58 | 0.090 |
Why?
|
| Superoxide Dismutase | 1 | 2011 | 170 | 0.080 |
Why?
|
| Weightlessness Countermeasures | 2 | 2008 | 6 | 0.080 |
Why?
|
| Rhabdomyosarcoma | 1 | 1992 | 208 | 0.070 |
Why?
|
| Musculoskeletal System | 1 | 2009 | 18 | 0.070 |
Why?
|
| Antioxidants | 1 | 2011 | 321 | 0.070 |
Why?
|
| Life Support Systems | 1 | 2008 | 5 | 0.070 |
Why?
|
| Kidney Medulla | 1 | 2008 | 19 | 0.070 |
Why?
|
| Taxoids | 2 | 2006 | 70 | 0.070 |
Why?
|
| Prednisone | 2 | 2006 | 240 | 0.070 |
Why?
|
| Kidney Calculi | 1 | 2008 | 45 | 0.070 |
Why?
|
| Cystostomy | 1 | 2007 | 3 | 0.070 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 2007 | 59 | 0.070 |
Why?
|
| Prostatic Neoplasms | 2 | 2006 | 1396 | 0.070 |
Why?
|
| In Vitro Techniques | 2 | 2007 | 822 | 0.070 |
Why?
|
| Geography | 1 | 2007 | 118 | 0.070 |
Why?
|
| Antigens | 1 | 2007 | 145 | 0.060 |
Why?
|
| Horses | 1 | 2007 | 103 | 0.060 |
Why?
|
| Lipid Peroxidation | 1 | 2007 | 90 | 0.060 |
Why?
|
| Animals | 5 | 2011 | 33051 | 0.060 |
Why?
|
| Chemoprevention | 1 | 2007 | 51 | 0.060 |
Why?
|
| Sus scrofa | 1 | 2007 | 115 | 0.060 |
Why?
|
| Sheep | 1 | 2007 | 224 | 0.060 |
Why?
|
| Radiation Dosage | 1 | 2007 | 126 | 0.060 |
Why?
|
| Immune System | 1 | 2007 | 92 | 0.060 |
Why?
|
| Thoracic Injuries | 1 | 2007 | 87 | 0.060 |
Why?
|
| Humans | 25 | 2019 | 126754 | 0.060 |
Why?
|
| Abdomen | 1 | 2007 | 132 | 0.060 |
Why?
|
| Cell Death | 1 | 2007 | 236 | 0.060 |
Why?
|
| Rabbits | 1 | 2007 | 614 | 0.060 |
Why?
|
| Calcinosis | 1 | 2008 | 184 | 0.060 |
Why?
|
| Cattle | 1 | 2007 | 537 | 0.060 |
Why?
|
| Abdominal Injuries | 1 | 2007 | 114 | 0.060 |
Why?
|
| Neoplasms, Hormone-Dependent | 1 | 2006 | 92 | 0.060 |
Why?
|
| Urologic Diseases | 1 | 2005 | 43 | 0.060 |
Why?
|
| Prostate-Specific Antigen | 1 | 2006 | 231 | 0.060 |
Why?
|
| Reproductive Techniques, Assisted | 1 | 2005 | 75 | 0.060 |
Why?
|
| Lymph Nodes | 1 | 2007 | 373 | 0.060 |
Why?
|
| Estramustine | 1 | 2004 | 3 | 0.060 |
Why?
|
| Nanoparticles | 1 | 2008 | 267 | 0.060 |
Why?
|
| Hemostatic Techniques | 1 | 2005 | 26 | 0.060 |
Why?
|
| Male | 14 | 2019 | 62543 | 0.060 |
Why?
|
| Physical Exertion | 1 | 2004 | 67 | 0.050 |
Why?
|
| Chromosome Aberrations | 1 | 2007 | 570 | 0.050 |
Why?
|
| Reactive Oxygen Species | 1 | 2007 | 493 | 0.050 |
Why?
|
| Ultrasonography | 3 | 2007 | 933 | 0.050 |
Why?
|
| Acute Disease | 1 | 2007 | 1135 | 0.050 |
Why?
|
| Upper Extremity | 1 | 2004 | 52 | 0.050 |
Why?
|
| Swine | 1 | 2007 | 1171 | 0.050 |
Why?
|
| Wounds and Injuries | 1 | 2007 | 377 | 0.050 |
Why?
|
| United States | 5 | 2009 | 11310 | 0.050 |
Why?
|
| Oxidative Stress | 1 | 2007 | 756 | 0.050 |
Why?
|
| Motion Sickness | 1 | 2002 | 10 | 0.050 |
Why?
|
| Equipment Design | 2 | 2004 | 575 | 0.050 |
Why?
|
| Testicular Neoplasms | 2 | 1995 | 120 | 0.050 |
Why?
|
| Physical Fitness | 1 | 2002 | 89 | 0.050 |
Why?
|
| Urinary Tract Infections | 1 | 2005 | 315 | 0.040 |
Why?
|
| Hemorrhage | 1 | 2005 | 492 | 0.040 |
Why?
|
| Occupational Diseases | 1 | 2001 | 75 | 0.040 |
Why?
|
| Lens, Crystalline | 1 | 2001 | 97 | 0.040 |
Why?
|
| Rats | 1 | 2007 | 3390 | 0.040 |
Why?
|
| Biomarkers | 2 | 2007 | 3222 | 0.040 |
Why?
|
| Cataract | 1 | 2001 | 142 | 0.040 |
Why?
|
| Weight Lifting | 1 | 2000 | 3 | 0.040 |
Why?
|
| Magnetic Resonance Imaging | 1 | 1992 | 3695 | 0.040 |
Why?
|
| Head Movements | 1 | 2000 | 16 | 0.040 |
Why?
|
| Intervertebral Disc | 1 | 2000 | 13 | 0.040 |
Why?
|
| Ergonomics | 1 | 2000 | 23 | 0.040 |
Why?
|
| Spinal Diseases | 1 | 2000 | 43 | 0.040 |
Why?
|
| Feasibility Studies | 2 | 2001 | 792 | 0.040 |
Why?
|
| Alendronate | 1 | 2019 | 21 | 0.040 |
Why?
|
| Posture | 1 | 2000 | 132 | 0.040 |
Why?
|
| Exercise | 2 | 2009 | 839 | 0.040 |
Why?
|
| Stress, Mechanical | 1 | 2000 | 169 | 0.040 |
Why?
|
| Bone Diseases, Metabolic | 1 | 2019 | 52 | 0.040 |
Why?
|
| Absorptiometry, Photon | 1 | 2019 | 193 | 0.040 |
Why?
|
| Osteoporosis | 1 | 2019 | 132 | 0.040 |
Why?
|
| Biomarkers, Tumor | 1 | 2006 | 1560 | 0.030 |
Why?
|
| United States National Aeronautics and Space Administration | 2 | 2008 | 20 | 0.030 |
Why?
|
| Radiation Protection | 2 | 2008 | 48 | 0.030 |
Why?
|
| Adenocarcinoma | 1 | 2004 | 973 | 0.030 |
Why?
|
| Bone and Bones | 1 | 2019 | 294 | 0.030 |
Why?
|
| Space Suits | 2 | 2007 | 3 | 0.030 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2001 | 508 | 0.030 |
Why?
|
| Mitoxantrone | 2 | 2006 | 27 | 0.030 |
Why?
|
| Adult | 5 | 2019 | 30410 | 0.030 |
Why?
|
| Image Cytometry | 1 | 1995 | 11 | 0.030 |
Why?
|
| Breast Neoplasms | 1 | 2007 | 2582 | 0.030 |
Why?
|
| Mice | 2 | 2011 | 17596 | 0.030 |
Why?
|
| DNA, Neoplasm | 1 | 1995 | 283 | 0.030 |
Why?
|
| Receptors, Platelet-Derived Growth Factor | 1 | 1993 | 18 | 0.030 |
Why?
|
| Platelet-Derived Growth Factor | 1 | 1993 | 42 | 0.030 |
Why?
|
| Prostatitis | 1 | 1993 | 20 | 0.020 |
Why?
|
| Prevalence | 1 | 2000 | 2591 | 0.020 |
Why?
|
| Risk Factors | 3 | 2007 | 10555 | 0.020 |
Why?
|
| Prostatic Hyperplasia | 1 | 1993 | 114 | 0.020 |
Why?
|
| Follow-Up Studies | 4 | 2006 | 5114 | 0.020 |
Why?
|
| Survival Analysis | 2 | 2006 | 1495 | 0.020 |
Why?
|
| Lethal Dose 50 | 1 | 2011 | 18 | 0.020 |
Why?
|
| Female | 6 | 2011 | 68330 | 0.020 |
Why?
|
| Androgens | 1 | 1993 | 268 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2000 | 3662 | 0.020 |
Why?
|
| Prostate | 1 | 1993 | 406 | 0.020 |
Why?
|
| Middle Aged | 5 | 2019 | 27697 | 0.020 |
Why?
|
| Time Factors | 3 | 2007 | 6134 | 0.020 |
Why?
|
| Ejaculation | 1 | 1990 | 21 | 0.020 |
Why?
|
| Retroperitoneal Neoplasms | 1 | 1990 | 31 | 0.020 |
Why?
|
| Receptors, Androgen | 1 | 1993 | 402 | 0.020 |
Why?
|
| Liposomes | 1 | 2011 | 196 | 0.020 |
Why?
|
| Plasmids | 1 | 2011 | 445 | 0.020 |
Why?
|
| Neoplasms, Germ Cell and Embryonal | 1 | 1990 | 85 | 0.020 |
Why?
|
| Lymph Node Excision | 1 | 1990 | 167 | 0.020 |
Why?
|
| Back Injuries | 1 | 2009 | 4 | 0.020 |
Why?
|
| Foot Injuries | 1 | 2009 | 7 | 0.020 |
Why?
|
| Health Facility Planning | 1 | 2008 | 3 | 0.020 |
Why?
|
| Time | 1 | 2008 | 94 | 0.020 |
Why?
|
| Extravehicular Activity | 1 | 2007 | 3 | 0.020 |
Why?
|
| Facility Design and Construction | 1 | 2007 | 5 | 0.020 |
Why?
|
| Arctic Regions | 1 | 2007 | 5 | 0.020 |
Why?
|
| Retrospective Studies | 3 | 2006 | 17005 | 0.020 |
Why?
|
| Dietary Supplements | 1 | 2011 | 438 | 0.020 |
Why?
|
| Virus Latency | 1 | 2007 | 61 | 0.020 |
Why?
|
| Technology Assessment, Biomedical | 1 | 2007 | 32 | 0.020 |
Why?
|
| Aged | 5 | 2006 | 20344 | 0.020 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2007 | 105 | 0.020 |
Why?
|
| Immunoglobulin M | 1 | 2007 | 209 | 0.020 |
Why?
|
| Immunophenotyping | 1 | 2007 | 330 | 0.020 |
Why?
|
| Canada | 1 | 2007 | 315 | 0.020 |
Why?
|
| Internationality | 1 | 2007 | 128 | 0.020 |
Why?
|
| Hydrocortisone | 1 | 2007 | 221 | 0.020 |
Why?
|
| Cells, Cultured | 2 | 2007 | 2893 | 0.020 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2007 | 199 | 0.020 |
Why?
|
| DNA, Viral | 1 | 2007 | 448 | 0.010 |
Why?
|
| Viral Load | 1 | 2007 | 398 | 0.010 |
Why?
|
| Multicenter Studies as Topic | 1 | 2006 | 290 | 0.010 |
Why?
|
| Stress, Physiological | 1 | 2007 | 257 | 0.010 |
Why?
|
| Dexamethasone | 1 | 2006 | 255 | 0.010 |
Why?
|
| Cumulative Trauma Disorders | 1 | 2004 | 7 | 0.010 |
Why?
|
| Herpesvirus 4, Human | 1 | 2007 | 613 | 0.010 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2007 | 477 | 0.010 |
Why?
|
| Nail Diseases | 1 | 2004 | 15 | 0.010 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2007 | 439 | 0.010 |
Why?
|
| Immunoglobulin G | 1 | 2007 | 762 | 0.010 |
Why?
|
| Aged, 80 and over | 2 | 2006 | 6668 | 0.010 |
Why?
|
| Diet | 1 | 2011 | 1100 | 0.010 |
Why?
|
| Kidney Transplantation | 1 | 1989 | 560 | 0.010 |
Why?
|
| Peripheral Nervous System Diseases | 1 | 2004 | 130 | 0.010 |
Why?
|
| Proportional Hazards Models | 1 | 2006 | 1364 | 0.010 |
Why?
|
| Clinical Trials as Topic | 1 | 2007 | 1102 | 0.010 |
Why?
|
| Antineoplastic Agents | 1 | 1992 | 1758 | 0.010 |
Why?
|
| Vasomotor System | 1 | 2002 | 20 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 1 | 2011 | 4504 | 0.010 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2006 | 1184 | 0.010 |
Why?
|
| Incidence | 1 | 2009 | 3251 | 0.010 |
Why?
|
| Cytokines | 1 | 2007 | 1320 | 0.010 |
Why?
|
| Oxygen Consumption | 1 | 2002 | 300 | 0.010 |
Why?
|
| Palliative Care | 1 | 2004 | 441 | 0.010 |
Why?
|
| Fluorouracil | 1 | 2001 | 132 | 0.010 |
Why?
|
| Predictive Value of Tests | 1 | 2006 | 2225 | 0.010 |
Why?
|
| Radiotherapy Dosage | 1 | 2001 | 194 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2007 | 2883 | 0.010 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2004 | 774 | 0.010 |
Why?
|
| Carcinoma, Transitional Cell | 1 | 2001 | 179 | 0.010 |
Why?
|
| Cisplatin | 1 | 2001 | 269 | 0.010 |
Why?
|
| T-Lymphocytes | 1 | 2007 | 1705 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2007 | 3586 | 0.010 |
Why?
|
| Longitudinal Studies | 1 | 2001 | 1428 | 0.010 |
Why?
|
| Combined Modality Therapy | 1 | 2001 | 1220 | 0.010 |
Why?
|
| Postoperative Complications | 1 | 1989 | 3066 | 0.010 |
Why?
|
| Child, Preschool | 1 | 1992 | 14347 | 0.010 |
Why?
|
| Survival Rate | 1 | 2001 | 2101 | 0.010 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2001 | 744 | 0.010 |
Why?
|
| Quality of Life | 1 | 2004 | 2029 | 0.010 |
Why?
|
| Cell Division | 1 | 1993 | 720 | 0.010 |
Why?
|
| Neoplasm Staging | 1 | 1995 | 1284 | 0.010 |
Why?
|
| Adrenergic Fibers | 1 | 1990 | 3 | 0.010 |
Why?
|
| Retroperitoneal Space | 1 | 1990 | 20 | 0.010 |
Why?
|
| Sympathetic Nervous System | 1 | 1990 | 55 | 0.010 |
Why?
|
| Cyclosporins | 1 | 1989 | 13 | 0.000 |
Why?
|
| Kidney Tubular Necrosis, Acute | 1 | 1989 | 9 | 0.000 |
Why?
|
| Lymphatic Metastasis | 1 | 1990 | 424 | 0.000 |
Why?
|
| Vascular Resistance | 1 | 1989 | 184 | 0.000 |
Why?
|
| Ureteral Obstruction | 1 | 1989 | 102 | 0.000 |
Why?
|
| Graft Rejection | 1 | 1989 | 553 | 0.000 |
Why?
|
| Treatment Outcome | 1 | 2001 | 12546 | 0.000 |
Why?
|
| Signal Transduction | 1 | 1993 | 4472 | 0.000 |
Why?
|